MDxHealth SA Dossier
Qualitative Analysis
Business overview
MDxHealth SA (NASDAQ: MDXH) is a commercial-stage precision diagnostics company specializing in urological solutions. Headquartered in Herstal, Belgium, with key operations in the United States and Europe, the company provides actionable molecular information to personalize patient diagnosis and treatment. Its comprehensive prostate cancer diagnostic menu includes Confirm mdx (a tissue-based epigenetic test validating negative biopsies), ExoDx (a non-invasive urine-based liquid test assessing high-grade cancer risk), and the Genomic Prostate Score (GPS) test (acquired from Exact Sciences to predict adverse pathology and guide treatment). Following strategic restructuring in mid-2026, the company discontinued its Resolve UTI business to focus entirely on its high-margin core prostate cancer diagnostics portfolio.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Discontinuing the Resolve UTI testing offering and closing the Plano, Texas laboratory facility due to an increasingly uncertain reimbursement landscape and a policy reversal by Medicare administrator Novitas. This proactive exit allows the company to focus its sales force and operating discipline entirely on its core prostate cancer precision diagnostics menu (Confirm mdx, Select mdx, ExoDx, and GPS mdx).
Expected impact: Resets the growth trajectory, eliminates reimbursement volatility, and redeploys commercial resources to high-value tissue- and liquid-based prostate cancer diagnostics.
Initiating a company-wide AI data platform and integrating Artificial Intelligence (AI) into every aspect of the business. This includes a collaboration with a customer-facing digital innovation company and incorporating AI-enhanced endpoints in the landmark Protect trial with the University of Oxford.
Expected impact: Aims to advance the prognostic value of the Genomic Prostate Score (GPS) test, support growth in tissue-based diagnostics, and drive operational efficiencies across the business.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of the ExoDx Prostate (EPI) liquid-based test, CLIA-certified clinical laboratory, and related assets. This addition solidifies MDxHealth's leadership in the precision diagnostics urology market and allows the transition of Select mdx customers to ExoDx, driving accelerated operating efficiencies.
Financial impact: Expected to contribute over $20 million in annual revenue and be immediately accretive to EBITDA operating profitability. Consideration includes $5 million in stock paid at closing ($4.5 million net of adjustments paid on October 1, 2025) and $2.5 million paid annually over the following 4 years (50% in cash and 50% in cash/stock).
Strategic Partnerships
A landmark clinical study (GPS PROTECT) encompassing over 1,500 patients to investigate the correlation between the Genomic Prostate Score (GPS) test and prostate cancer progression following treatment. It aims to provide the highest level of clinical evidence to support active surveillance decisions and drive clinical and payer adoption.
Terms: Not disclosed.